

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Corti et al.

Application No.: **10/622,817**

Filed: **July 18, 2003**

Title: **METHOD FOR DETERMINING THE ABILITY OF
A COMPOUND TO MODIFY THE
INTERACTION BETWEEN PARKIN AND
THE p38 PROTEIN**



Examiner: **Unknown**

Art Unit: **1614**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

Sept. 30, 2004
Date of Receipt

Delia Coughlin
Signature

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.



- (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,

Karen I. Krupen, Reg. No. 34,647
Attorney for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4658
Telefax (908) 231-2626
Aventis Docket No. FRAV2002/0020USNP

☒

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/622,817
Filing Date	07-18-2003
First Named Inventor	CORTI
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	FRAV2002/0020 - US - NP

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

[illegible][illegible]

Examiner Signature		Date Considered
-----------------------	--	--------------------

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

+

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/622,817
Filing Date	07-18-2003
First Named Inventor	CORTI
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	FRAV2002/0020 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ABBAS, Nacer et al., A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe, Human Molecular Genetics, (1999), Vol. 8, No. 4, pp. 567 - 574	
		ALTSCHUL Stephen F. et al., Basic Local Alignment Search Tool, Journal Molecular Biology, (1990), Vol. 215, pp. 403 - 410	
		ALTSCHUL Stephen F. et al., Gapped BLAST And PSI-BLAST: A New Generation Of Protein Database Search Programs, Nucleic Acids Research, (1997), Vol. 25, No. 17, pp. 3389 - 3402	
		C.B. LUCKING et al., Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism, The Lancet, Vol. 352, Oct. 24, 1998, pp. 1355-1356	
		E. LEROY et al., The ubiquitin pathway in Parkinson's disease, Nature, Vol. 395, Oct. 1, 1998, pp. 451-452	
		E. MORETT et al., A novel transactivation domain in parkin, Trends in Biochem Sci., Vol. 24, June 1999, pp. 229-231	
		H. SHIMURA et al., Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase, Nature Genetics, Vol. 25, July 2000, pp. 302-305	
		H. SHIMURA et al., Immunohistochemical and Subcellular Localization of Parkin Protein: Absence of Protein in Autosomal Recessive Juvenile Parkinsonism Patients, Ann. Neurol. Vol. 45, 1999, pp. 668-672	
		M. POLYMERPOULOS et al., Mutation in the alpha-synuclein gene identified in families with Parkinson's Disease, Science, Vol. 276, June 27, 1997, pp. 2045-2047	
		N. HATTORI et al., Molecular Genetic Analysis of a Novel Parkin Gene in Japanese Families with Autosomal Recessive Juvenile Parkinsonism: Evidence for Variable Homozygous Deletions in the Parkin Gene in Affected Individuals, Annals of Neurology, Vol. 44, Issue 3, 1998, pp. 935-941	

Examiner
Signature

Date
Considered

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	10/622,817
Filing Date	07-18-2003
First Named Inventor	CORTI
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	FRAV2002/0020 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		R. KOPITO, Aggresomes, inclusion bodies and protein aggregation, Trends in Cell Biology, Vol. 10, Dec. 2000, pp. 524-530	
		R.K. BRACHMANN et al., Tag games in yeast: the two-hybrid system and beyond, Current Opinion Biotechnol. Vol. 8, No. 5, Oct. 1997, pp. 561-568	
		S. FIELDS et al., A novel genetic system to detect protein-protein interactions, Nature, Vol. 340, July 20, 1989, pp. 245-246	
		S. QUEVILLON et al., Macromolecular Assemblage of Aminoacyl-tRNA Synthetases: Identification of Protein-Protein Interactions and Characterization of a Core Protein, J. Mol. Biol. Vol. 285, 1999, pp. 183-195	
		Sanger et al., DNA sequencing with chain-terminating inhibitors, Proc. Natl. Acad. Sci. 74(12), 5463-5467 (1977)	
		T. KITADA et al., Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism, Nature, Vol. 392, April 9, 1998, pp. 605-608	
		T.R. FLOTTE et al., Gene Expression from Adeno-associated Virus Vectors in Airway Epithelial Cells, Am. J. Respir. Cell Mol. Biol., Vol. 7, 1992, pp. 349-356	
		Y. IMAI et al., Parkin Suppresses Unfolded Protein Stress-induced Cell Death through its E3 Ubiquitin-protein Ligase Activity, Journ. of Biol. Chem., Vol. 275, No. 46, Nov. 17, 2000, pp. 35661-35664	
		Y. SUNADA et al., Differential expression of the parkin gene in the human brain and peripheral leukocytes, Neuroscience Letters, Vol. 254, pp. 180-182	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.